The company’s prior guidance was $1.0B-$1.1B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions: Upcoming Quarterly Earnings Discussion
- Emergent Biosolutions Divests RSDL Rights in $75M Deal
- Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
- Emergent BioSolutions completes sale of RSDL Kit to SERB for $75M
- Emergent BioSolutions Executive Jennifer Fox Resigns